Insights into the structure, function, and regulation of human cytochrome P450 1A2

Current Drug Metabolism

Volumn 10, Issue 7, 2009, Pages 713-729

  Zhou, Shu Feng ^a   Yang, Li Ping ^a   Wei, Ming Qian ^b   Duan, Wei ^c   Chan, Eli ^d  

^a RMIT UNIVERSITY   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

^c DEAKIN UNIVERSITY   (Australia)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Aromatic hydrocarbon receptor; CYP1A2; Inducer; Inhibitor; Substrate

Indexed keywords

ALPHA NAPHTHOFLAVONE; APIGENIN; ARISTOLOCHIC ACID; AROMATIC HYDROCARBON RECEPTOR; CARCINOGEN; CELECOXIB; CIPROFLOXACIN; CLOZAPINE; COUMARIN; CYCLOBENZAPRINE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 3A4; DIURON; ISOSAFROLE; LEFLUNOMIDE; LIDOCAINE; MELATONIN; OLTIPRAZ; PHENAZONE; POLYCYCLIC AROMATIC HYDROCARBON; PROPOFOL; RETINOID; RILUZOLE; ROFECOXIB; TACRINE; THEOPHYLLINE; UNINDEXED DRUG; VENLAFAXINE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CRYSTAL STRUCTURE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; ENZYME STRUCTURE; GENE FUNCTION; HORMONE METABOLISM; HUMAN; HYDROXYLATION; IC 50; NONHUMAN; REGULATORY MECHANISM; REVIEW;

ANIMALS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; ENZYME INHIBITORS; HUMANS; LIVER; MICE; MICE, KNOCKOUT; PHARMACEUTICAL PREPARATIONS;

EID: 66449111462     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920009789895552     Document Type: Review

References (295)

1. Shimada, T.; Yamazaki, H.; Mimura, M.; Inui, Y.; Guengerich, F. P. Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals. J. Pharmacol. Exp. Ther., 1994, 270(1), 414-423.
2. Schweikl, H.; Taylor, J. A.; Kitareewan, S.; Linko, P.; Nagorney, D.; Goldstein, J. A. Expression of CYP1A1 and CYP1A2 genes in human liver. Pharmacogenetics, 1993, 3(5), 239-249.
3. Paine, M. F.; Schmiedlin-Ren, P.; Watkins, P. B. Cytochrome P-450 1A1 expression in human small bowel: interindividual variation and inhibition by ketoconazole. Drug Metab. Dispos., 1999, 27(3), 360-364.
4. Prueksaritanont, T.; Gorham, L. M.; Hochman, J. H.; Tran, L. O.; Vyas, K. P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos., 1996, 24(6), 634-642.
5. Shimada, T.; Yamazaki, H.; Mimura, M.; Wakamiya, N.; Ueng, Y. F.; Guengerich, F. P.; Inui, Y. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab. Dispos., 1996, 24(5), 515-522.
6. Willey, J. C.; Coy, E. L.; Frampton, M. W.; Torres, A.; Apostolakos, M. J.; Hoehn, G.; Schuermann, W. H.; Thilly, W. G.; Olson, D. E.; Hammersley, J. R.; Crespi, C. L.; Utell, M. J. Quantitative RT-PCR measurement of cytochromes P450 1A1, 1B1, and 2B7, microsomal epoxide hydrolase, and NADPH oxidoreductase expression in lung cells of smokers and nonsmokers. Am. J. Respir. Cell. Mol. Biol., 1997, 17(1), 114-124.
7. Hakkola, J.; Pasanen, M.; Hukkanen, J.; Pelkonen, O.; Maenpaa, J.; Edwards, R. J.; Boobis, A. R.; Raunio, H. Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. Biochem. Pharmacol., 1996, 51(4), 403-411.
8. Vanden Heuvel, J. P.; Clark, G. C.; Thompson, C. L.; McCoy, Z.; Miller, C. R.; Lucier, G. W.; Bell, D. A. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative polymerase chain reaction to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis, 1993, 14(10), 2003-2006.
9. Dey, A.; Parmar, D.; Dayal, M.; Dhawan, A.; Seth, P. K. Cytochrome P450 1A1 (CYP1A1) in blood lymphocytes evidence for catalytic activity and mRNA expression. Life Sci., 2001, 69(4), 383-393.
10. van Duursen, M. B.; Sanderson, J. T.; van den Berg, M. Cytochrome P450 1A1 and 1B1 in human blood lymphocytes are not suitable as biomarkers of exposure to dioxin-like compounds: polymorphisms and interindividual variation in expression and inducibility. Toxicol. Sci., 2005, 85(1), 703-712.
11. Walton, K.; Dorne, J. L.; Renwick, A. G. Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. Food Chem. Toxicol., 2001, 39(7), 667-680.
12. Eagling, V. A.; Tjia, J. F.; Back, D. J. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes. Br. J. Clin. Pharmacol., 1998, 45(2), 107-114.
13. Gunes, A.; Dahl, M. L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics, 2008, 9(5), 625-637.
14. Ikeya, K.; Jaiswal, A. K.; Owens, R. A.; Jones, J. E.; Nebert, D. W.; Kimura, S. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol. Endocrinol., 1989, 3(9), 1399-1408.
15. Rasmussen, B. B.; Brix, T. H.; Kyvik, K. O.; Brosen, K. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics, 2002, 12(6), 473-478.
16. Waxman, D. J.; Chang, T. K. Use of 7-ethoxycoumarin to monitor multiple enzymes in the human CYP1, CYP2, and CYP3 families. Methods Mol. Biol., 2006, 320, 153-156.
17. Yamazaki, H.; Inoue, K.; Mimura, M.; Oda, Y.; Guengerich, F. P.; Shimada, T. 7-Ethoxycoumarin O-deethylation catalyzed by cytochromes P450 1A2 and 2E1 in human liver microsomes. Biochem. Pharmacol., 1996, 51(3), 313-319.
18. Chang, T. K.; Waxman, D. J. Enzymatic analysis of cDNAexpressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Methods Mol. Biol., 2006, 320, 85-90.
19. Bartoli, A.; Xiaodong, S.; Gatti, G.; Cipolla, G.; Marchiselli, R.; Perucca, E. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther. Drug Monit., 1996, 18(5), 586-591.
20. Kalow, W.; Tang, B. K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther., 1991, 49(1), 44-48.
21. Tassaneeyakul, W.; Mohamed, Z.; Birkett, D. J.; McManus, M. E.; Veronese, M. E.; Tukey, R. H.; Quattrochi, L. C.; Gonzalez, F. J.; Miners, J. O. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics, 1992, 2(4), 173-183.
22. Carrillo, J. A.; Christensen, M.; Ramos, S. I.; Alm, C.; Dahl, M. L.; Benitez, J.; Bertilsson, L. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther. Drug Monit., 2000, 22(4), 409-417.
23. Ryu, J. Y.; Song, I. S.; Sunwoo, Y. E.; Shon, J. H.; Liu, K. H.; Cha, I. J.; Shin, J. G. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo. Clin. Pharmacol. Ther., 2007, 82(5), 531-540.
24. Tassaneeyakul, W.; Birkett, D. J.; McManus, M. E.; Tassaneeyakul, W.; Veronese, M. E.; Andersson, T.; Tukey, R. H.; Miners, J. O. Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. Biochem. Pharmacol., 1994, 47(10), 1767-1776.
25. Ha, H. R.; Chen, J.; Freiburghaus, A. U.; Follath, F. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br. J. Clin. Pharmacol., 1995, 39(3), 321-326.
26. Sarkar, M. A.; Hunt, C.; Guzelian, P. S.; Karnes, H. T. Characterization of human liver cytochromes P450 involved in theophylline metabolism. Drug Metab. Dispos., 1992, 20(1), 31-37.
27. Zhang, Z. Y.; Kaminsky, L. S. Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem. Pharmacol., 1995, 50(2), 205-211.
28. Sarkar, M. A.; Jackson, B. J. Theophylline N-demethylations as probes for P4501A1 and P4501A2. Drug Metab. Dispos., 1994, 22(6), 827-834.
29. Tjia, J. F.; Colbert, J.; Back, D. J. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol. Exp. Ther., 1996, 276(3), 912-917.
30. Gu, L.; Gonzalez, F. J.; Kalow, W.; Tang, B. K. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics, 1992, 2(2), 73-77.
31. Tassaneeyakul, W.; Birkett, D. J.; Veronese, M. E.; McManus, M. E.; Tukey, R. H.; Quattrochi, L. C.; Gelboin, H. V.; Miners, J. O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther., 1993, 265(1), 401-407.
32. Niwa, T.; Sato, R.; Yabusaki, Y.; Ishibashi, F.; Katagiri, M. Contribution of human hepatic cytochrome P450s and steroidogenic CYP17 to the N-demethylation of aminopyrine. Xenobiotica, 1999, 29(2), 187-193.
33. Nakajima, M.; Kobayashi, K.; Shimada, N.; Tokudome, S.; Yamamoto, T.; Kuroiwa, Y. Involvement of CYP1A2 in mexiletine metabolism. Br. J. Clin. Pharmacol., 1998, 46(1), 55-62.
34. Ohyama, K.; Nakajima, M.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. A significant role of human cytochrome P4502C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metab. Dispos., 2000, 28(11), 1303-1310.
35. Zhou, Q.; Yao, T. W.; Yu, Y. N.; Zeng, S. Concentration dependent stereoselectivity of propafenone N-depropylation metabolism with human hepatic recombinant CYP1A2. Pharmazie, 2003, 58(9), 651-653.
36. Botsch, S.; Gautier, J. C.; Beaune, P.; Eichelbaum, M.; Kroemer, H. K. Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol. Pharmacol., 1993, 43(1), 120-126.
37. Ikeda, K.; Yoshisue, K.; Matsushima, E.; Nagayama, S.; Kobayashi, K.; Tyson, C. A.; Chiba, K.; Kawaguchi, Y. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro. Clin. Cancer Res., 2000, 6(11), 4409-4415.
38. Komatsu, T.; Yamazaki, H.; Shimada, N.; Nakajima, M.; Yokoi, T. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab. Dispos., 2000, 28(12), 1457-1463.
39. Goda, R.; Nagai, D.; Akiyama, Y.; Nishikawa, K.; Ikemoto, I.; Aizawa, Y.; Nagata, K.; Yamazoe, Y. Detection of a new N-oxidized metabolite of flutamide, N-[4-nitro-3-(trifluoromethyl) phenyl]hydroxylamine, in human liver microsomes and urine of prostate cancer patients. Drug Metab. Dispos., 2006, 34(5), 828-835.
40. Shet, M. S.; McPhaul, M.; Fisher, C. W.; Stallings, N. R.; Estabrook, R. W. Metabolism of the antiandrogenic drug (Flutamide) by human CYP1A2. Drug Metab. Dispos., 1997, 25(11), 1298-1303.
41. Miyata, M.; Tamura, E.; Motoki, K.; Nagata, K.; Yamazoe, Y. Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation. Drug Metab. Dispos., 2003, 31(4), 469-475.
42. Uttamsingh, V.; Lu, C.; Miwa, G.; Gan, L. S. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab. Dispos., 2005, 33(11), 1723-1728.
43. Zhou, S.; Paxton, J. W.; Tingle, M. D.; Kestell, P. Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab. Dispos., 2000, 28(12), 1449-1456.
44. Zhou, S.; Kestell, P.; Paxton, J. W. Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab. Rev., 2002, 34(4), 751-790.
45. Thijssen, H. H.; Flinois, J. P.; Beaune, P. H. Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab. Dispos., 2000, 28(11), 1284-1290.
46. Hermans, J. J.; Thijssen, H. H. Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br. J. Pharmacol., 1993, 110(1), 482-490.
47. Kaminsky, L. S.; Zhang, Z. Y. Human P450 metabolism of warfarin. Pharmacol. Ther., 1997, 73(1), 67-74.
48. Olesen, O. V.; Linnet, K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P450 isozymes. Drug Metab. Dispos., 1997, 25(6), 740-744.
49. Mellstrom, B.; von Bahr, C. Demethylation and hydroxylation of amitriptyline, nortriptyline, and 10-hydroxyamitriptyline in human liver microsomes. Drug Metab. Dispos., 1981, 9(6), 565-568.
50. Venkatakrishnan, K.; von Moltke, L. L.; Obach, R. S.; Greenblatt, D. J. Microsomal binding of amitriptyline: effect on estimation of enzyme kinetic parameters in vitro. J. Pharmacol. Exp. Ther., 2000, 293(2), 343-350.
51. Venkatakrishnan, K.; Schmider, J.; Harmatz, J. S.; Ehrenberg, B. L.; von Moltke, L. L.; Graf, J. A.; Mertzanis, P.; Corbett, K. E.; Rodriguez, M. C.; Shader, R. I.; Greenblatt, D. J. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J. Clin. Pharmacol., 2001, 41(10), 1043-1054.
52. Koyama, E.; Chiba, K.; Tani, M.; Ishizaki, T. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J. Pharmacol. Exp. Ther., 1997, 281(3), 1199-1210.
53. Wu, Z. L.; Huang, S. L.; Ou-Yang, D. S.; Xu, Z. H.; Xie, H. G.; Zhou, H. H. Clomipramine N-demethylation metabolism in human liver microsomes. Zhongguo Yao Li Xue Bao, 1998, 19(5), 433-436.
54. Nielsen, K. K.; Flinois, J. P.; Beaune, P.; Brosen, K. The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J. Pharmacol. Exp. Ther., 1996, 277(3), 1659-1664.
55. Lobo, E. D.; Bergstrom, R. F.; Reddy, S.; Quinlan, T.; Chappell, J.; Hong, Q.; Ring, B.; Knadler, M. P. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin. Pharmacokinet., 2008, 47(3), 191-202.
56. Brachtendorf, L.; Jetter, A.; Beckurts, K. T.; Holscher, A. H.; Fuhr, U. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol. Toxicol., 2002, 90(3), 144-149.
57. Stormer, E.; von Moltke, L. L.; Shader, R. I.; Greenblatt, D. J. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P450 1A2, 2D6, and 3A4. Drug Metab. Dispos., 2000, 28(10), 1168-1175.
58. Koyama, E.; Chiba, K.; Tani, M.; Ishizaki, T. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J. Pharmacol. Exp. Ther., 1996, 278(1), 21-30.
59. Nakajima, M.; Nakamura, S.; Tokudome, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab. Dispos., 1999, 27(12), 1381-1391.
60. Kariya, S.; Isozaki, S.; Uchino, K.; Suzuki, T.; Narimatsu, S. Oxidative metabolism of flunarizine and cinnarizine by microsomes from B-lymphoblastoid cell lines expressing human cytochrome P450 enzymes. Biol. Pharm. Bull., 1996, 19(11), 1511-1514.
61. Narimatsu, S.; Kariya, S.; Isozaki, S.; Ohmori, S.; Kitada, M.; Hosokawa, S.; Masubuchi, Y.; Suzuki, T. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem. Biophys. Res. Commun., 1993, 193(3), 1262-1268.
62. Akutsu, T.; Kobayashi, K.; Sakurada, K.; Ikegaya, H.; Furihata, T.; Chiba, K. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab. Dispos., 2007, 35(1), 72-78.
63. Kroemer, H. K.; Gautier, J. C.; Beaune, P.; Henderson, C.; Wolf, C. R.; Eichelbaum, M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch. Pharmacol., 1993, 348(3), 332-337.
64. Kudo, S.; Okumura, H.; Miyamoto, G.; Ishizaki, T. Cytochrome P-450 isoforms involved in carboxylic acid ester cleavage of Hantzsch pyridine ester of pranidipine. Drug Metab. Dispos., 1999, 27(2), 303-308.
65. Clement, B.; Demesmaeker, M. Formation of guanoxabenz from guanabenz in human liver. A new metabolic marker for CYP1A2. Drug Metab. Dispos., 1997, 25(11), 1266-1271.
66. McEnroe, J. D.; Fleishaker, J. C. Clinical pharmacokinetics of almotriptan, a serotonin 5-HT1B/1D receptor agonist for the treatment of migraine. Clin. Pharmacokinet., 2005, 44(3), 237-246.
67. Wild, M. J.; McKillop, D.; Butters, C. J. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica, 1999, 29(8), 847-857.
68. Bertilsson, L.; Carrillo, J. A.; Dahl, M. L.; Llerena, A.; Alm, C.; Bondesson, U.; Lindstrom, L.; Rodriguez de la Rubia, I.; Ramos, S.; Benitez, J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol., 1994, 38(5), 471-473.
69. Fang, J.; McKay, G.; Song, J.; Remillrd, A.; Li, X.; Midha, K. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes. Drug Metab. Dispos., 2001, 29(12), 1638-1643.
70. Wojcikowski, J.; Pichard-Garcia, L.; Maurel, P.; Daniel, W. A. Contribution of human cytochrome P450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br. J. Pharmacol., 2003, 138(8), 1465-1474.
71. Ring, B. J.; Catlow, J.; Lindsay, T. J.; Gillespie, T.; Roskos, L. K.; Cerimele, B. J.; Swanson, S. P.; Hamman, M. A.; Wrighton, S. A. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J. Pharmacol. Exp. Ther., 1996, 276(2), 658-666.
72. Shiraga, T.; Kaneko, H.; Iwasaki, K.; Tozuka, Z.; Suzuki, A.; Hata, T. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica, 1999, 29(3), 217-229.
73. Wojcikowski, J.; Maurel, P.; Daniel, W. A. Characterization of human cytochrome P450 enzymes involved in the metabolism of the piperidine-type phenothiazine neuroleptic thioridazine. Drug Metab. Dispos., 2006, 34(3), 471-476.
74. Masubuchi, Y.; Hosokawa, S.; Horie, T.; Suzuki, T.; Ohmori, S.; Kitada, M.; Narimatsu, S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos., 1994, 22(6), 909-915.
75. Oldham, H. G.; Clarke, S. E. In vitro identification of the human cytochrome P450 enzymes involved in the metabolism of R(+)- and S(-)-carvedilol. Drug Metab. Dispos., 1997, 25(8), 970-977.
76. Slaughter, D.; Takenaga, N.; Lu, P.; Assang, C.; Walsh, D. J.; Arison, B. H.; Cui, D.; Halpin, R. A.; Geer, L. A.; Vyas, K. P.; Baillie, T. A. Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab. Dispos., 2003, 31(11), 1398-1408.
77. Pichard, L.; Gillet, G.; Bonfils, C.; Domergue, J.; Thenot, J. P.; Maurel, P. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab. Dispos., 1995, 23(11), 1253-1262.
78. Machinist, J. M.; Mayer, M. D.; Shet, M. S.; Ferrero, J. L.; Rodrigues, A. D. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbott-66193. Drug Metab. Dispos., 1995, 23(10), 1163-1174.
79. Orlando, R.; Piccoli, P.; De Martin, S.; Padrini, R.; Floreani, M.; Palatini, P. Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin. Pharmacol. Ther., 2004, 75(1), 80-88.
80. Oda, Y.; Furuichi, K.; Tanaka, K.; Hiroi, T.; Imaoka, S.; Asada, A.; Fujimori, M.; Funae, Y. Metabolism of a new local anesthetic, ropivacaine, by human hepatic cytochrome P450. Anesthesiology, 1995, 82(1), 214-220.
81. Salonen, J. S.; Nyman, L.; Boobis, A. R.; Edwards, R. J.; Watts, P.; Lake, B. G.; Price, R. J.; Renwick, A. B.; Gomez-Lechon, M. J.; Castell, J. V.; Ingelman-Sundberg, M.; Hidestrand, M.; Guillouzo, A.; Corcos, L.; Goldfarb, P. S.; Lewis, D. F.; Taavitsainen, P.; Pelkonen, O. Comparative studies on the cytochrome P450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems. Drug Metab. Dispos., 2003, 31(9), 1093-1102.
82. Ward, B. A.; Gorski, J. C.; Jones, D. R.; Hall, S. D.; Flockhart, D. A.; Desta, Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther., 2003, 306(1), 287-300.
83. Carrillo, J. A.; Dahl, M. L.; Svensson, J. O.; Alm, C.; Rodriguez, I.; Bertilsson, L. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin. Pharmacol. Ther., 1996, 60(2), 183-190.
84. Dixon, C. M.; Colthup, P. V.; Serabjit-Singh, C. J.; Kerr, B. M.; Boehlert, C. C.; Park, G. R.; Tarbit, M. H. Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab. Dispos., 1995, 23(11), 1225-1230.
85. Spaldin, V.; Madden, S.; Pool, W. F.; Woolf, T. F.; Park, B. K. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol., 1994, 38(1), 15-22.
86. Spaldin, V.; Madden, S.; Adams, D. A.; Edwards, R. J.; Davies, D. S.; Park, B. K. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab. Dispos., 1995, 23(9), 929-934.
87. Fuhr, U.; Kober, S.; Zaigler, M.; Mutschler, E.; Spahn-Langguth, H. Rate-limiting biotransformation of triamterene is mediated by CYP1A2. Int. J. Clin. Pharmacol. Ther., 2005, 43(7), 327-334.
88. Pearce, R. E.; Vakkalagadda, G. R.; Leeder, J. S. Pathways of carbamazepine bioactivation in vitro I. Characterization of human cytochromes P450 responsible for the formation of 2- and 3-hydroxylated metabolites. Drug Metab. Dispos., 2002, 30(11), 1170-1179.
89. Wolkenstein, P.; Tan, C.; Lecoeur, S.; Wechsler, J.; Garcia-Martin, N.; Charue, D.; Bagot, M.; Beaune, P. Covalent binding of carbamazepine reactive metabolites to P450 isoforms present in the skin. Chem. Biol. Interact., 1998, 113(1), 39-50.
90. Pelkonen, O.; Myllynen, P.; Taavitsainen, P.; Boobis, A. R.; Watts, P.; Lake, B. G.; Price, R. J.; Renwick, A. B.; Gomez-Lechon, M. J.; Castell, J. V.; Ingelman-Sundberg, M.; Hidestrand, M.; Guillouzo, A.; Corcos, L.; Goldfarb, P. S.; Lewis, D. F. V. Carbamazepine: a 'blind' assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica, 2001, 31(6), 321-343.
91. Granfors, M. T.; Backman, J. T.; Laitila, J.; Neuvonen, P. J. Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. Br. J. Clin. Pharmacol., 2004, 57(3), 349-353.
92. Vickers, A. E.; Sinclair, J. R.; Zollinger, M.; Heitz, F.; Glanzel, U.; Johanson, L.; Fischer, V. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos., 1999, 27(9), 1029-1038.
93. Chen, C.; Meng, L.; Ma, X.; Krausz, K. W.; Pommier, Y.; Idle, J. R.; Gonzalez, F. J. Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J. Pharmacol. Exp. Ther., 2006, 318(3), 1330-1342.
94. Qizilbash, N.; Whitehead, A.; Higgins, J.; Wilcock, G.; Schneider, L.; Farlow, M. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. Jama, 1998, 280(20), 1777-1782.
95. Gupta, A. K.; Shear, N. H. Terbinafine: an update. J. Am. Acad. Dermatol., 1997, 37(6), 979-988.
96. Wagstaff, A. J.; Bryson, H. M. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs, 1997, 53(3), 435-452.
97. Wang, R. W.; Liu, L.; Cheng, H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab. Dispos., 1996, 24(7), 786-791.
98. Miners, J. O.; Coulter, S.; Tukey, R. H.; Veronese, M. E.; Birkett, D. J. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem. Pharmacol., 1996, 51(8), 1003-1008.
99. Kalgutkar, A. S.; Nguyen, H. T.; Vaz, A. D.; Doan, A.; Dalvie, D. K.; McLeod, D. G.; Murray, J. C. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos., 2003, 31(10), 1240-1250.
100. Silverman, E.; Mouy, R.; Spiegel, L.; Jung, L. K.; Saurenmann, R. K.; Lahdenne, P.; Horneff, G.; Calvo, I.; Szer, I. S.; Simpson, K.; Stewart, J. A.; Strand, V. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N. Engl. J. Med., 2005, 352(16), 1655-1666.
101. Guitton, J.; Buronfosse, T.; Desage, M.; Flinois, J. P.; Perdrix, J. P.; Brazier, J. L.; Beaune, P. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br. J. Anaesth., 1998, 80(6), 788-795.
102. Miller, R. G.; Mitchell, J. D.; Lyon, M.; Moore, D. H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev., 2007, 1, CD001447.
103. Radunovic, A.; Mitsumoto, H.; Leigh, P. N. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol., 2007, 6(10), 913-925.
104. Wokke, J. Riluzole. Lancet, 1996, 348(9030), 795-799.
105. Bryson, H. M.; Fulton, B.; Benfield, P. Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs, 1996, 52(4), 549-563.
106. Groeneveld, G. J.; van Kan, H. J.; Lie, A. H. L.; Guchelaar, H. J.; van den Berg, L. H. An association study of riluzole serum concentration and survival and disease progression in patients with ALS. Clin. Pharmacol. Ther., 2008, 83(5), 718-722.
107. Sanderink, G. J.; Bournique, B.; Stevens, J.; Petry, M.; Martinet, M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J. Pharmacol. Exp. Ther., 1997, 282(3), 1465-1472.
108. Uckun, F. M.; Thoen, J.; Chen, H.; Sudbeck, E.; Mao, C.; Malaviya, R.; Liu, X. P.; Chen, C. L. CYP1A-mediated metabolism of the Janus kinase-3 inhibitor 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline: structural basis for inactivation by regioselective O-demethylation. Drug Metab. Dispos., 2002, 30(1), 74-85.
109. Guengerich, F. P.; Shimada, T. Activation of procarcinogens by human cytochrome P450 enzymes. Mutat. Res., 1998, 400(1-2), 201-213.
110. Oda, Y.; Aryal, P.; Terashita, T.; Gillam, E. M.; Guengerich, F. P.; Shimada, T. Metabolic activation of heterocyclic amines and other procarcinogens in Salmonella typhimurium umu tester strains expressing human cytochrome P4501A1, 1A2, 1B1, 2C9, 2D6, 2E1, and 3A4 and human NADPH-P450 reductase and bacterial O-acetyltransferase. Mutat. Res., 2001, 492(1-2), 81-90.
111. Buters, J. T.; Shou, M.; Hardwick, J. P.; Korzekwa, K. R.; Gonzalez, F. J. cDNA-directed expression of human cytochrome P450 CYP1A1 using baculovirus. Purification, dependency on NADPH-P450 oxidoreductase, and reconstitution of catalytic properties without purification. Drug Metab. Dispos., 1995, 23(7), 696-701.
112. Shou, M.; Gonzalez, F. J.; Gelboin, H. V. Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons by cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry, 1996, 35(49), 15807-15813.
113. Ma, Q.; Lu, A. Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos., 2007, 35(7), 1009-1016.
114. Shimada, T.; Gillam, E. M.; Oda, Y.; Tsumura, F.; Sutter, T. R.; Guengerich, F. P.; Inoue, K. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7, 8-dihydrobenzo[a]pyrene by recombinant human cytochrome P450 1B1 and purified liver epoxide hydrolase. Chem. Res. Toxicol., 1999, 12(7), 623-629.
115. Shimada, T.; Hayes, C. L.; Yamazaki, H.; Amin, S.; Hecht, S. S.; Guengerich, F. P.; Sutter, T. R. Activation of chemically diverse procarcinogens by human cytochrome P450 1B1. Cancer Res., 1996, 56(13), 2979-2984.
116. Ueng, Y. F.; Shimada, T.; Yamazaki, H.; Guengerich, F. P. Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 1995, 8(2), 218-225.
117. Sengstag, C.; Eugster, H. P.; Wurgler, F. E. High promutagen activating capacity of yeast microsomes containing human cytochrome P-450 1A and human NADPH-cytochrome P-450 reductase. Carcinogenesis, 1994, 15(5), 837-843.
118. Penman, B. W.; Chen, L.; Gelboin, H. V.; Gonzalez, F. J.; Crespi, C. L. Development of a human lymphoblastoid cell line constitutively expressing human CYP1A1 cDNA: substrate specificity with model substrates and promutagens. Carcinogenesis, 1994, 15(9), 1931-1937.
119. Crespi, C. L.; Penman, B. W.; Steimel, D. T.; Smith, T.; Yang, C. S.; Sutter, T. R. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagenesis, 1997, 12(2), 83-89.
120. Gillam, E. M.; Baba, T.; Kim, B. R.; Ohmori, S.; Guengerich, F. P. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys., 1993, 305(1), 123-131.
121. Abass, K.; Reponen, P.; Turpeinen, M.; Jalonen, J.; Pelkonen, O. Characterization of diuron N-demethylation by mammalian hepatic microsomes and cDNA-expressed human cytochrome P450 enzymes. Drug Metab. Dispos., 2007, 35(9), 1634-1641.
122. Stresser, D. M.; Kupfer, D. Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of CYP2C19 and CYP1A2 in O-demethylation. Drug Metab. Dispos., 1998, 26(9), 868-874.
123. Bulger, W. H.; Muccitelli, R. M.; Kupfer, D. Studies on the in vivo and in vitro estrogenic activities of methoxychlor and its metabolites. Role of hepatic mono-oxygenase in methoxychlor activation. Biochem. Pharmacol., 1978, 27(20), 2417-2423.
124. Drinkwater, N. R.; Miller, E. C.; Miller, J. A.; Pitot, H. C. Hepatocarcinogenicity of estragole (1-allyl-4-methoxybenzene) and 1′-hydroxyestragole in the mouse and mutagenicity of 1′- acetoxyestragole in bacteria. J. Natl. Cancer Inst., 1976, 57(6), 1323-1331.
125. Anthony, A.; Caldwell, J.; Hutt, A. J.; Smith, R. L. Metabolism of estragole in rat and mouse and influence of dose size on excretion of the proximate carcinogen 1'-hydroxyestragole. Food Chem. Toxicol., 1987, 25(11), 799-806.
126. Jeurissen, S. M.; Punt, A.; Boersma, M. G.; Bogaards, J. J.; Fiamegos, Y. C.; Schilter, B.; Bladeren, P. J.; Cnubben, N. H.; Rietjens, I. M. Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem. Res. Toxicol., 2007, 20(5): 798-806.
127. Borchert, P.; Wislocki, P. G.; Miller, J. A.; Miller, E. C. The metabolism of the naturally occurring hepatocarcinogen safrole to 1′-hydroxysafrole and the electrophilic reactivity of 1'-acetoxysafrole. Cancer Res., 1973, 33(3), 575-589.
128. Jeurissen, S. M.; Bogaards, J. J.; Awad, H. M.; Boersma, M. G.; Brand, W.; Fiamegos, Y. C.; van Beek, T. A.; Alink, G. M.; Sudholter, E. J.; Cnubben, N. H.; Rietjens, I. M. Human cytochrome P450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1′-hydroxysafrole. Chem. Res. Toxicol., 2004, 17(9), 1245-1250.
129. Ueng, Y. F.; Hsieh, C. H.; Don, M. J.; Chi, C. W.; Ho, L. K. Identification of the main human cytochrome P450 enzymes involved in safrole 1′-hydroxylation. Chem. Res. Toxicol., 2004, 17(8), 1151-1156.
130. Jeurissen, S. M.; Bogaards, J. J.; Boersma, M. G.; ter Horst, J. P.; Awad, H. M.; Fiamegos, Y. C.; van Beek, T. A.; Alink, G. M.; Sudholter, E. J.; Cnubben, N. H.; Rietjens, I. M. Human cytochrome P450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethyleugenol. Chem. Res. Toxicol., 2006, 19(1), 111-116.
131. Gardner, I.; Wakazono, H.; Bergin, P.; de Waziers, I.; Beaune, P.; Kenna, J. G.; Caldwell, J. Cytochrome P450 mediated bioactivation of methyleugenol to 1'-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes. Carcinogenesis, 1997, 18(9), 1775-1783.
132. Zhou, S. F. Drug bioactivation and covalent binding to target proteins and toxicity relevance. Drug Metab. Rev., 2005, 37(1): 41-213.
133. Zhou, S. F.; Xue, C. C.; Yu, X. Q.; Wang, G. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr. Drug Metab., 2007, 8(6), 526-553.
134. Stiborova, M.; Frei, E.; Wiessler, M.; Schmeiser, H. H. Human enzymes involved in the metabolic activation of carcinogenic aris tolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol., 2001, 14(8), 1128-1137.
135. Stiborova, M.; Frei, E.; Sopko, B.; Wiessler, M.; Schmeiser, H. H. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis, 2002, 23(4), 617-625.
136. Stiborova, M.; Frei, E.; Wiessler, M.; Schmeiser, H. H. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem. Res. Toxicol., 2001, 14(8), 1128-1137.
137. 32P-postlabeling analysis of DNA adduct formation. Mutat. Res., 2001, 493(1-2), 149-160.
138. 32P-post-labelling: evidence for reductive activation by peroxidases. Carcinogenesis, 1997, 18(5), 1055-1062.
139. Born, S. L.; Caudill, D.; Fliter, K. L.; Purdon, M. P. Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metab. Dispos., 2002, 30(5), 483-487.
140. Yun, C. H.; Shimada, T.; Guengerich, F. P. Purification and characterization of human liver microsomal cytochrome P450 2A6. Mol. Pharmacol., 1991, 40(5), 679-685.
141. Li, Y.; Li, N. Y.; Sellers, E. M. Comparison of CYP2A6 catalytic activity on coumarin 7-hydroxylation in human and monkey liver microsomes. Eur. J. Drug Metab. Pharmacokinet., 1997, 22(4), 295-304.
142. Soucek, P. Expression of cytochrome P450 2A6 in Escherichia coli: purification, spectral and catalytic characterization, and preparation of polyclonal antibodies. Arch. Biochem. Biophys., 1999, 370(2), 190-200.
143. Miles, J. S.; McLaren, A. W.; Forrester, L. M.; Glancey, M. J.; Lang, M. A.; Wolf, C. R. Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity. Biochem. J., 1990, 267(2), 365-371.
144. Jamal, S.; Casley-Smith, J. R.; Casley-Smith, J. R. The effects of 5,6 benzo-[a]-pyrone (coumarin) and DEC on filaritic lymphoedema and elephantiasis in India. Preliminary results. Ann. Trop. Med. Parasitol., 1989, 83(3), 287-290.
145. Marshall, M. E.; Mohler, J. L.; Edmonds, K.; Williams, B.; Butler, K.; Ryles, M.; Weiss, L.; Urban, D.; Bueschen, A.; Markiewicz, M.; et al. An updated review of the clinical development of coumarin (1,2-benzopyrone) and 7-hydroxycoumarin. J. Cancer Res. Clin. Oncol., 1994, 120(Suppl), S39-42.
146. Kulling, S. E.; Lehmann, L.; Metzler, M. Oxidative metabolism and genotoxic potential of major isoflavone phytoestrogens. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2002, 777(1-2), 211-218.
147. Hu, M.; Krausz, K.; Chen, J.; Ge, X.; Li, J.; Gelboin, H. L.; Gonzalez, F. J. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab. Dispos., 2003, 31(7), 924-931.
148. Tolleson, W. H.; Doerge, D. R.; Churchwell, M. I.; Marques, M. M.; Roberts, D. W. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J. Agric. Food Chem., 2002, 50(17), 4783-4790.
149. Breinholt, V. M.; Rasmussen, S. E.; Brosen, K.; Friedberg, T. H. In vitro metabolism of genistein and tangeretin by human and murine cytochrome P450s. Pharmacol. Toxicol., 2003, 93(1), 14-22.
150. Otake, Y.; Walle, T. Oxidation of the flavonoids galangin and kaempferide by human liver microsomes and CYP1A1, CYP1A2, and CYP2C9. Drug Metab. Dispos., 2002, 30(2), 103-105.
151. Yamazaki, H.; Inoue, K.; Hashimoto, M.; Shimada, T. Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch. Toxicol., 1999, 73(2), 65-70.
152. Murphy, S. E.; Raulinaitis, V.; Brown, K. M. Nicotine 5′-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab. Dispos., 2005, 33(8), 1166-1173.
153. Hecht, S. S.; Hochalter, J. B.; Villalta, P. W.; Murphy, S. E. 2′-Hydroxylation of nicotine by cytochrome P450 2A6 and human liver microsomes: formation of a lung carcinogen precursor. Proc. Natl. Acad. Sci. USA, 2000, 97(23), 12493-12497.
154. Messina, E. S.; Tyndale, R. F.; Sellers, E. M. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J. Pharmacol. Exp. Ther., 1997, 282(3), 1608-1614.
155. Berkman, C. E.; Park, S. B.; Wrighton, S. A.; Cashman, J. R. In vitro-in vivo correlations of human S-nicotine metabolism. Biochem. Pharmacol., 1995, 50(4), 565-570.
156. Nakajima, M.; Yamamoto, T.; Nunoya, K.; Yokoi, T.; Nagashima, K.; Inoue, K.; Funae, Y.; Shimada, N.; Kamataki, T.; Kuroiwa, Y. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab. Dispos., 1996, 24(11), 1212-1217.
157. Skene, D. J.; Papagiannidou, E.; Hashemi, E.; Snelling, J.; Lewis, D. F.; Fernandez, M.; Ioannides, C. Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices. J. Pineal Res., 2001, 31(4), 333-342.
158. -/- mutant mice. Biochem. Pharmacol., 2001, 61(7), 843-849.
159. Lambrecht, R. W.; Sinclair, P. R.; Gorman, N.; Sinclair, J. F. Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch. Biochem. Biophys., 1992, 294(2), 504-510.
160. Yamazaki, H.; Shaw, P. M.; Guengerich, F. P.; Shimada, T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem. Res. Toxicol., 1998, 11(6), 659-665.
161. Lee, A. J.; Cai, M. X.; Thomas, P. E.; Conney, A. H.; Zhu, B. T. Characterization of the oxidative metabolites of 17β-estradiol and estrone formed by 15 selectively expressed human cytochrome P450 isoforms. Endocrinology, 2003, 144(8), 3382-3398.
162. Lee, A. J.; Kosh, J. W.; Conney, A. H.; Zhu, B. T. Characterization of the NADPH-dependent metabolism of 17β-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. J. Pharmacol. Exp. Ther., 2001, 298(2), 420-432.
163. Ma, X.; Idle, J. R.; Krausz, K. W.; Gonzalez, F. J. Metabolism of melatonin by human cytochromes P450. Drug Metab. Dispos., 2005, 33(4), 489-494.
164. Young, I. M.; Leone, R. M.; Francis, P.; Stovell, P.; Silman, R. E. Melatonin is metabolized to N-acetyl serotonin and 6-hydroxymelatonin in man. J. Clin. Endocrinol. Metab., 1985, 60(1), 114-119.
165. Sinclair, P. R.; Gorman, N.; Tsyrlov, I. B.; Fuhr, U.; Walton, H. S.; Sinclair, J. F. Uroporphyrinogen oxidation catalyzed by human cytochromes P450. Drug Metab. Dispos., 1998, 26(10), 1019-1025.
166. Chen, H.; Howald, W. N.; Juchau, M. R. Biosynthesis of all-transretinoic acid from all-trans-retinol: catalysis of all-trans-retinol oxidation by human P450 cytochromes. Drug Metab. Dispos., 2000, 28(3), 315-322.
167. Zhang, Q. Y.; Dunbar, D.; Kaminsky, L. Human cytochrome P450 metabolism of retinals to retinoic acids. Drug Metab. Dispos., 2000, 28(3), 292-297.
168. Choudhary, D.; Jansson, I.; Stoilov, I.; Sarfarazi, M.; Schenkman, J. B. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab. Dispos., 2004, 32(8), 840-847.
169. Rifkind, A. B.; Lee, C.; Chang, T. K.; Waxman, D. J. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch. Biochem. Biophys., 1995, 320(2), 380-389.
170. Bylund, J.; Kunz, T.; Valmsen, K.; Oliw, E. H. Cytochromes P450 with bisallylic hydroxylation activity on arachidonic and linoleic acids studied with human recombinant enzymes and with human and rat liver microsomes. J. Pharmacol. Exp. Ther., 1998, 284(1), 51-60.
171. Masubuchi, Y.; Nakano, T.; Ose, A.; Horie, T. Differential selectivity in carbamazepine-induced inactivation of cytochrome P450 enzymes in rat and human liver. Arch. Toxicol., 2001, 75(9), 538-543.
172. Masubuchi, Y.; Horie, T. Dihydralazine-induced inactivation of cytochrome P450 enzymes in rat liver microsomes. Drug Metab. Dispos., 1998, 26(4), 338-342.
173. Kunze, K. L.; Trager, W. F. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem. Res. Toxicol., 1993, 6(5), 649-656.
174. Wen, X.; Wang, J. S.; Neuvonen, P. J.; Backman, J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol., 2002, 57(11), 799-804.
175. Karjalainen, M. J.; Neuvonen, P. J.; Backman, J. T. Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. Drug Metab. Dispos., 2006, 34(12), 2091-2096.
176. Lu, P.; Schrag, M. L.; Slaughter, D. E.; Raab, C. E.; Shou, M.; Rodrigues, A. D. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab. Dispos., 2003, 31(11), 1352-1360.
177. Ohyama, K.; Nakajima, M.; Suzuki, M.; Shimada, N.; Yamazaki, H.; Yokoi, T. Inhibitory effects of amiodarone and its Ndeethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br. J. Clin. Pharmacol., 2000, 49(3), 244-253.
178. Langouet, S.; Furge, L. L.; Kerriguy, N.; Nakamura, K.; Guillouzo, A.; Guengerich, F. P. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem. Res. Toxicol., 2000, 13(4), 245-252.
179. Chang, T. K.; Chen, J.; Lee, W. B. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J. Pharmacol. Exp. Ther., 2001, 299(3), 874-882.
180. Shimada, T.; Murayama, N.; Okada, K.; Funae, Y.; Yamazaki, H.; Guengerich, F. P. Different mechanisms for inhibition of human cytochromes P450 1A1, 1A2, and 1B1 by polycyclic aromatic inhibitors. Chem. Res. Toxicol., 2007, 20(3), 489-496.
181. Di Consiglio, E.; Meneguz, A.; Testai, E. Organophosphorothionate pesticides inhibit the bioactivation of imipramine by human hepatic cytochrome P450s. Toxicol. Appl. Pharmacol., 2005, 205(3), 237-246.
182. St Peter, J. V.; Braeckman, R. A.; Granneman, G. R.; Locke, C. S.; Cavanaugh, J. H.; Awni, W. M. The effect of zileuton on antipyrine and indocyanine green disposition. Clin. Pharmacol. Ther., 1995, 57(3), 299-308.
183. Lau, R. Drug interactions with zileuton. Lancet, 1997, 349(9063), 1479-1480.
184. Awni, W. M.; Hussein, Z.; Granneman, G. R.; Patterson, K. J.; Dube, L. M.; Cavanaugh, J. H. Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans. Clin. Pharmacokinet., 1995, 29(Suppl 2), 67-76.
185. Granneman, G. R.; Braeckman, R. A.; Locke, C. S.; Cavanaugh, J. H.; Dube, L. M.; Awni, W. M. Effect of zileuton on theophylline pharmacokinetics. Clin. Pharmacokinet., 1995, 29(Suppl 2),77-83.
186. Samara, E.; Cavanaugh, J. H.; Mukherjee, D.; Granneman, G. R. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans. Clin. Pharmacokinet., 1995, 29(Suppl 2), 84-91.
187. Awni, W. M.; Hussein, Z.; Cavanaugh, J. H.; Granneman, G. R.; Dube, L. M. Assessment of the pharmacokinetic interaction between zileuton and digoxin in humans. Clin. Pharmacokinet., 1995, 29(Suppl 2), 92-97.
188. Awni, W. M.; Braeckman, R. A.; Cavanaugh, J. H.; Locke, C. S.; Linnen, P. J.; Granneman, G. R.; Dube, L. M. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclooxygenase inhibitor naproxen in human volunteers. Clin. Pharmacokinet., 1995, 29(Suppl 2), 112-124.
189. Awni, W. M.; Cavanaugh, J. H.; Tzeng, T. B.; Witt, G.; Granneman, G. R.; Dube, L. M. Pharmacokinetic interactions between zileuton and prednisone. Clin. Pharmacokinet., 1995, 29(Suppl 2), 105-111.
190. Awni, W. M.; Braeckman, R. A.; Locke, C. S.; Dube, L. M.; Granneman, G. R. The influence of multiple oral doses of zileuton on the steady-state pharmacokinetics of sulfasalazine and its metabolites, sulfapyridine and N-acetylsulfapyridine. Clin. Pharmacokinet., 1995, 29(Suppl 2), 98-104.
191. Awni, W. M.; Cavanaugh, J. H.; Leese, P.; Kasier, J.; Cao, G.; Locke, C. S.; Dube, L. M. The pharmacokinetic and pharmacodynamic interaction between zileuton and terfenadine. Eur. J. Clin. Pharmacol., 1997, 52(1), 49-54.
192. Bachmann, K.; White, D.; Jauregui, L.; Schwartz, J. I.; Agrawal, N. G.; Mazenko, R.; Larson, P. J.; Porras, A. G. An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J. Clin. Pharmacol., 2003, 43(10), 1082-1090.
193. Schwartz, J. I.; Bugianesi, K. J.; Ebel, D. L.; De Smet, M.; Haesen, R.; Larson, P. J.; Ko, A.; Verbesselt, R.; Hunt, T. L.; Lins, R.; Lens, S.; Porras, A. G.; Dieck, J.; Keymeulen, B.; Gertz, B. J. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin. Clin. Pharmacol. Ther., 2000, 68(6), 626-636.
194. Backman, J. T.; Karjalainen, M. J.; Neuvonen, M.; Laitila, J.; Neuvonen, P. J. Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br. J. Clin. Pharmacol., 2006, 62(3), 345-357.
195. Becquemont, L.; Ragueneau, I.; Le Bot, M. A.; Riche, C.; Funck-Brentano, C.; Jaillon, P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin. Pharmacol. Ther., 1997, 61(6), 619-627.
196. Brosen, K.; Skjelbo, E.; Rasmussen, B. B.; Poulsen, H. E.; Loft, S. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem. Pharmacol., 1993, 45(6), 1211-1214.
197. von Moltke, L. L.; Greenblatt, D. J.; Duan, S. X.; Schmider, J.; Kudchadker, L.; Fogelman, S. M.; Harmatz, J. S.; Shader, R. I. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology (Berl), 1996, 128(4), 398-407.
198. Rasmussen, B. B.; Maenpaa, J.; Pelkonen, O.; Loft, S.; Poulsen, H. E.; Lykkesfeldt, J.; Brosen, K. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Br. J. Clin. Pharmacol., 1995, 39(2), 151-159.
199. Pastrakuljic, A.; Tang, B. K.; Roberts, E. A.; Kalow, W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochem. Pharmacol., 1997, 53(4), 531-538.
200. Abernethy, D. R.; Todd, E. L. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur. J. Clin. Pharmacol., 1985, 28(4), 425-428.
201. Parker, A. C.; Preston, T.; Heaf, D.; Kitteringham, N. R.; Choonara, I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test. Br. J. Clin. Pharmacol., 1994, 38(6), 573-576.
202. Granfors, M. T.; Backman, J. T.; Neuvonen, M.; Neuvonen, P. J. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin. Pharmacol. Ther., 2004, 76(6), 598-606.
203. Kobayashi, K.; Nakajima, M.; Chiba, K.; Yamamoto, T.; Tani, M.; Ishizaki, T.; Kuroiwa, Y. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. Br. J. Clin. Pharmacol., 1998, 45(4), 361-368.
204. Niwa, T.; Inoue-Yamamoto, S.; Shiraga, T.; Takagi, A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull., 2005, 28(9), 1813-1816.
205. Martinez, C.; Albet, C.; Agundez, J. A.; Herrero, E.; Carrillo, J. A.; Marquez, M.; Benitez, J.; Ortiz, J. A. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin. Pharmacol. Ther., 1999, 65(4), 369-376.
206. Karjalainen, M. J.; Neuvonen, P. J.; Backman, J. T. Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo. Eur. J. Clin. Pharmacol., 2008, 64(5), 511-519.
207. Ball, S. E.; Ahern, D.; Scatina, J.; Kao, J. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br. J. Clin. Pharmacol., 1997, 43(6), 619-626.
208. Zhai, S.; Dai, R.; Friedman, F. K.; Vestal, R. E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos., 1998, 26(10), 989-992.
209. Ueng, Y. F.; Jan, W. C.; Lin, L. C.; Chen, T. L.; Guengerich, F. P.; Chen, C. F. The alkaloid rutaecarpine is a selective inhibitor of cy tochrome P450 1A in mouse and human liver microsomes. Drug Metab. Dispos., 2002, 30(3), 349-353.
210. Chun, Y. J.; Kim, M. Y.; Guengerich, F. P. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Commun., 1999, 262(1), 20-24.
211. Piver, B.; Berthou, F.; Dreano, Y.; Lucas, D. Differential inhibition of human cytochrome P450 enzymes by ε-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages. Life Sci., 2003, 73(9), 1199-1213.
212. Chun, Y. J.; Ryu, S. Y.; Jeong, T. C.; Kim, M. Y. Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab. Dispos., 2001, 29(4 Pt 1), 389-393.
213. Sansen, S.; Yano, J. K.; Reynald, R. L.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem., 2007, 282(19), 14348-14355.
214. Schoch, G. A.; Yano, J. K.; Wester, M. R.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site. J. Biol. Chem., 2004, 279(10), 9497-9503.
215. Yano, J. K.; Hsu, M. H.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat. Struct. Mol. Biol., 2005, 12(9), 822-823.
216. Wester, M. R.; Johnson, E. F.; Marques-Soares, C.; Dijols, S.; Dansette, P. M.; Mansuy, D.; Stout, C. D. Structure of mammalian cytochrome P450 2C5 complexed with diclofenac at 2.1 A resolution: evidence for an induced fit model of substrate binding. Biochemistry, 2003, 42(31), 9335-9345.
217. Wester, M. R.; Stout, C. D.; Johnson, E. F. Purification and crystallization of N-terminally truncated forms of microsomal cytochrome P450 2C5. Methods Enzymol., 2002, 357, 73-79.
218. Williams, P. A.; Cosme, J.; Sridhar, V.; Johnson, E. F.; McRee, D. E. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol. Cell, 2000, 5(1), 121-131.
219. Ozalp, C.; Szczesna-Skorupa, E.; Kemper, B. Identification of membrane-contacting loops of the catalytic domain of cytochrome P450 2C2 by tryptophan fluorescence scanning. Biochemistry, 2006, 45(14), 4629-4637.
220. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 2003, 424(6947), 464-468.
221. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J. Biol. Chem., 2004, 279(34), 35630-35637.
222. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of human cytochrome P450 2D6. J. Biol. Chem., 2006, 281(11), 7614-7622.
223. Scott, E. E.; White, M. A.; He, Y. A.; Johnson, E. F.; Stout, C. D.; Halpert, J. R. Structure of mammalian cytochrome P450 2B4 complexed with 4-(4-chlorophenyl)imidazole at 1.9-Å resolution: insight into the range of P450 conformations and the coordination of redox partner binding. J. Biol. Chem., 2004, 279(26), 27294-27301.
224. Williams, P. A.; Cosme, J.; Vinkovic, D. M.; Ward, A.; Angove, H. C.; Day, P. J.; Vonrhein, C.; Tickle, I. J.; Jhoti, H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science, 2004, 305(5684), 683-686.
225. Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-Å resolution. J. Biol. Chem., 2004, 279(37), 38091-38094.
226. Shimada, T.; Yamazaki, H.; Foroozesh, M.; Hopkins, N. E.; Alworth, W. L.; Guengerich, F. P. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1. Chem. Res. Toxicol., 1998, 11(9), 1048-1056.
227. Cho, U. S.; Park, E. Y.; Dong, M. S.; Park, B. S.; Kim, K.; Kim, K. H. Tight-binding inhibition by α-naphthoflavone of human cytochrome P450 1A2. Biochim. Biophys. Acta, 2003, 1648(1-2), 195-202.
228. Liu, J.; Ericksen, S. S.; Sivaneri, M.; Besspiata, D.; Fisher, C. W.; Szklarz, G. D. The effect of reciprocal active site mutations in human cytochromes P450 1A1 and 1A2 on alkoxyresorufin metabolism. Arch. Biochem. Biophys., 2004, 424(1), 33-43.
229. Backman, J. T.; Granfors, M. T.; Neuvonen, P. J. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur. J. Clin. Pharmacol., 2006, 62(6), 451-461.
230. Fontana, R. J.; Lown, K. S.; Paine, M. F.; Fortlage, L.; Santella, R. M.; Felton, J. S.; Knize, M. G.; Greenberg, A.; Watkins, P. B. Effects of a chargrilled meat diet on expression of CYP3A, CYP1A, and P-glycoprotein levels in healthy volunteers. Gastroenterology, 1999, 117(1), 89-98.
231. Wietholtz, H.; Voegelin, M.; Arnaud, M. J.; Bircher, J.; Preisig, R. Assessment of the cytochrome P448 dependent liver enzyme system by a caffeine breath test. Eur. J. Clin. Pharmacol., 1981, 21(1), 53-59.
232. Zevin, S.; Benowitz, N. L. Drug interactions with tobacco smoking. An update. Clin. Pharmacokinet., 1999, 36(6), 425-438.
233. Grygiel, J. J.; Birkett, D. J. Cigarette smoking and theophylline clearance and metabolism. Clin. Pharmacol. Ther., 1981, 30(4), 491-496.
234. Han, X. M.; Ouyang, D. S.; Chen, X. P.; Shu, Y.; Jiang, C. H.; Tan, Z. R.; Zhou, H. H. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J. Clin. Pharmacol., 2002, 54(5), 540-543.
235. Yoshinari, K.; Ueda, R.; Kusano, K.; Yoshimura, T.; Nagata, K.; Yamazoe, Y. Omeprazole transactivates human CYP1A1 and CYP1A2 expression through the common regulatory region containing multiple xenobiotic-responsive elements. Biochem. Pharmacol., 2008, 76(1), 139-145.
236. Diaz, D.; Fabre, I.; Daujat, M.; Saint Aubert, B.; Bories, P.; Michel, H.; Maurel, P. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology, 1990, 99(3), 737-747.
237. Masubuchi, N.; Li, A. P.; Okazaki, O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem. Biol. Interact., 1998, 114(1-2), 1-13.
238. Rost, K. L.; Brosicke, H.; Brockmoller, J.; Scheffler, M.; Helge, H.; Roots, I. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of '-mephenytoin. Clin. Pharmacol. Ther., 1992, 52(2), 170-180.
239. Rost, K. L.; Fuhr, U.; Thomsen, T.; Zaigler, M.; Brockmoller, J.; Bohnemeier, H.; Roots, I. Omeprazole weakly inhibits CYP1A2 activity in man. Int. J. Clin. Pharmacol. Ther., 1999, 37(11), 567-574.
240. Rost, K. L.; Brosicke, H.; Heinemeyer, G.; Roots, I. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology, 1994, 20(5), 1204-1212.
241. Andersson, T.; Bergstrand, R.; Cederberg, C.; Eriksson, S.; Lagerstrom, P. O.; Skanberg, I. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology, 1991, 101(4), 943-947.
242. Hartmann, M.; Zech, K.; Bliesath, H.; Steinijans, V. W.; Koch, H.; Wurst, W.; Mascher, H. Pantoprazole lacks induction of CYP1A2 activity in man. Int. J. Clin. Pharmacol. Ther., 1999, 37(4), 159-164.
243. Rizzo, N.; Padoin, C.; Palombo, S.; Scherrmann, J. M.; Girre, C. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur. J. Clin. Pharmacol., 1996, 49(6), 491-495.
244. Nebert, D. W.; Dalton, T. P.; Okey, A. B.; Gonzalez, F. J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem., 2004, 279(23), 23847-23850.
245. Ma, Q. Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles. Curr. Drug Metab., 2001, 2(2), 149-164.
246. Burbach, K. M.; Poland, A.; Bradfield, C. A. Cloning of the Ahreceptor cDNA reveals a distinctive ligand-activated transcription factor. Proc. Natl. Acad. Sci. U. S. A., 1992, 89(17), 8185-8189.
247. Goryo, K.; Suzuki, A.; Del Carpio, C. A.; Siizaki, K.; Kuriyama, E.; Mikami, Y.; Kinoshita, K.; Yasumoto, K.; Rannug, A.; Miyamoto, A.; Fujii-Kuriyama, Y.; Sogawa, K. Identification of amino acid residues in the Ah receptor involved in ligand binding. Biochem. Biophys. Res. Commun., 2007, 354(2), 396-402.
248. Kumar, M. B.; Ramadoss, P.; Reen, R. K.; Vanden Heuvel, J. P.; Perdew, G. H. The Q-rich subdomain of the human Ah receptor transactivation domain is required for dioxin-mediated transcriptional activity. J. Biol. Chem., 2001, 276(45), 42302-42310.
249. Dolwick, K. M.; Schmidt, J. V.; Carver, L. A.; Swanson, H. I.; Bradfield, C. A. Cloning and expression of a human Ah receptor cDNA. Mol. Pharmacol., 1993, 44(5), 911-917.
250. Ogiso, H.; Kagi, N.; Matsumoto, E.; Nishimoto, M.; Arai, R.; Shirouzu, M.; Mimura, J.; Fujii-Kuriyama, Y.; Yokoyama, S. Phosphorylation analysis of 90 kDa heat shock protein within the cytosolic arylhydrocarbon receptor complex. Biochemistry, 2004, 43(49), 15510-15519.
251. Petrulis, J. R.; Kusnadi, A.; Ramadoss, P.; Hollingshead, B.; Perdew, G. H. The hsp90 Co-chaperone XAP2 alters importin-β recognition of the bipartite nuclear localization signal of the Ah receptor and represses transcriptional activity. J. Biol. Chem., 2003, 278(4), 2677-2685.
252. Petrulis, J. R.; Hord, N. G.; Perdew, G. H. Subcellular localization of the aryl hydrocarbon receptor is modulated by the immunophilin homolog hepatitis B virus X-associated protein 2. J. Biol. Chem., 2000, 275(48), 37448-37453.
253. Hollingshead, B. D.; Patel, R. D.; Perdew, G. H. Endogenous hepatic expression of the hepatitis B virus X-associated protein 2 is adequate for maximal association with aryl hydrocarbon receptor-90-kDa heat shock protein complexes. Mol. Pharmacol., 2006, 70(6), 2096-2107.
254. Carver, L. A.; LaPres, J. J.; Jain, S.; Dunham, E. E.; Bradfield, C. A. Characterization of the Ah receptor-associated protein, ARA9. J. Biol. Chem., 1998, 273(50), 33580-33587.
255. Carver, L. A.; Jackiw, V.; Bradfield, C. A. The 90-kDa heat shock protein is essential for Ah receptor signaling in a yeast expression system. J. Biol. Chem., 1994, 269(48), 30109-30112.
256. Denison, M. S.; Nagy, S. R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol., 2003, 43(309-334.
257. Kubota, M.; Sogawa, K.; Kaizu, Y.; Sawaya, T.; Watanabe, J.; Kawajiri, K.; Gotoh, O.; Fujii-Kuriyama, Y. Xenobiotic responsive element in the 5′-upstream region of the human P-450c gene. J. Biochem., 1991, 110(2), 232-236.
258. Fujisawa-Sehara, A.; Sogawa, K.; Yamane, M.; Fujii-Kuriyama, Y. Characterization of xenobiotic responsive elements upstream from the drug-metabolizing cytochrome P-450c gene: a similarity to glucocorticoid regulatory elements. Nucleic Acids Res., 1987, 15(10), 4179-4191.
259. Zhang, L.; Zheng, W.; Jefcoate, C. R. Ah receptor regulation of mouse Cyp1B1 is additionally modulated by a second novel complex that forms at two AhR response elements. Toxicol. Appl. Pharmacol., 2003, 192(2), 174-190.
260. Zhang, L.; Savas, U.; Alexander, D. L.; Jefcoate, C. R. Characterization of the mouse Cyp1B1 gene. Identification of an enhancer region that directs aryl hydrocarbon receptor-mediated constitutive and induced expression. J. Biol. Chem., 1998, 273(9), 5174-5183.
261. Yueh, M. F.; Huang, Y. H.; Hiller, A.; Chen, S.; Nguyen, N.; Tukey, R. H. Involvement of the xenobiotic response element (XRE) in Ah receptor-mediated induction of human UDP-glucuronosyltransferase 1A1. J. Biol. Chem., 2003, 278(17), 15001-15006.
262. Mimura, J.; Ema, M.; Sogawa, K.; Fujii-Kuriyama, Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev., 1999, 13(1), 20-25.
263. Watanabe, T.; Imoto, I.; Kosugi, Y.; Fukuda, Y.; Mimura, J.; Fujii, Y.; Isaka, K.; Takayama, M.; Sato, A.; Inazawa, J. Human arylhydrocarbon receptor repressor (AHRR) gene: genomic structure and analysis of polymorphism in endometriosis. J. Hum. Genet., 2001, 46(6), 342-346.
264. Baba, T.; Mimura, J.; Gradin, K.; Kuroiwa, A.; Watanabe, T.; Matsuda, Y.; Inazawa, J.; Sogawa, K.; Fujii-Kuriyama, Y. Structure and expression of the Ah receptor repressor gene. J. Biol. Chem., 2001, 276(35), 33101-33110.
265. Evans, B. R.; Karchner, S. I.; Allan, L. L.; Pollenz, R. S.; Tanguay, R. L.; Jenny, M. J.; Sherr, D. H.; Hahn, M. E. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. Mol. Pharmacol., 2008, 73(2), 387-398.
266. Haarmann-Stemmann, T.; Bothe, H.; Kohli, A.; Sydlik, U.; Abel, J.; Fritsche, E. Analysis of the transcriptional regulation and molecular function of the aryl hydrocarbon receptor repressor in human cell lines. Drug Metab Dispos, 2007, 35(12), 2262-2269.
267. Haarmann-Stemmann, T.; Abel, J. The arylhydrocarbon receptor repressor (AhRR): structure, expression, and function. Biol. Chem., 2006, 387(9), 1195-1199.
268. Fernandez-Salguero, P. M.; Hilbert, D. M.; Rudikoff, S.; Ward, J. M.; Gonzalez, F. J. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol., 1996, 140(1), 173-179.
269. -/- mice. Science, 1996, 271(5246), 223-224.
270. Fernandez-Salguero, P.; Pineau, T.; Hilbert, D. M.; McPhail, T.; Lee, S. S.; Kimura, S.; Nebert, D. W.; Rudikoff, S.; Ward, J. M.; Gonzalez, F. J. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science, 1995, 268(5211), 722-726.
271. Shimizu, Y.; Nakatsuru, Y.; Ichinose, M.; Takahashi, Y.; Kume, H.; Mimura, J.; Fujii-Kuriyama, Y.; Ishikawa, T. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(2), 779-782.
272. Harstad, E. B.; Guite, C. A.; Thomae, T. L.; Bradfield, C. A. Liver deformation in Ahr-null mice: evidence for aberrant hepatic perfusion in early development. Mol. Pharmacol., 2006, 69(5), 1534-1541.
273. Kozak, K. R.; Abbott, B.; Hankinson, O. ARNT-deficient mice and placental differentiation. Dev. Biol., 1997, 191(2), 297-305.
274. Lin, B. C.; Sullivan, R.; Lee, Y.; Moran, S.; Glover, E.; Bradfield, C. A. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Biol. Chem., 2007, 282(49), 35924-35932.
275. Hosoya, T.; Harada, N.; Mimura, J.; Motohashi, H.; Takahashi, S.; Nakajima, O.; Morita, M.; Kawauchi, S.; Yamamoto, M.; Fujii-Kuriyama, Y. Inducibility of cytochrome P450 1A1 and chemical carcinogenesis by benzo[a]pyrene in AhR repressor-deficient mice. Biochem. Biophys. Res. Commun., 2008, 365(3), 562-567.
276. Ema, M.; Ohe, N.; Suzuki, M.; Mimura, J.; Sogawa, K.; Ikawa, S.; Fujii-Kuriyama, Y. Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J. Biol. Chem., 1994, 269(44), 27337-27343.
277. Okey, A. B.; Vella, L. M.; Harper, P. A. Detection and characterization of a low affinity form of cytosolic Ah receptor in livers of mice nonresponsive to induction of cytochrome P1-450 by 3-methylcholanthrene. Mol. Pharmacol., 1989, 35(6), 823-830.
278. Song, J.; Clagett-Dame, M.; Peterson, R. E.; Hahn, M. E.; Westler, W. M.; Sicinski, R. R.; DeLuca, H. F. A ligand for the aryl hydrocarbon receptor isolated from lung. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(23), 14694-14699.
279. Backlund, M.; Johansson, I.; Mkrtchian, S.; Ingelman-Sundberg, M. Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells. J. Biol. Chem., 1997, 272(50), 31755-31763.
280. Ishida, S.; Jinno, H.; Tanaka-Kagawa, T.; Ando, M.; Ohno, Y.; Ozawa, S.; Sawada, J. Characterization of human CYP1A1/1A2 induction by DNA microarray and alpha-naphthoflavone. Biochem. Biophys. Res. Commun., 2002, 296(1), 172-177.
281. Tang, C.; Lin, J. H.; Lu, A. Y. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction? Drug Metab. Dispos., 2005, 33(5), 603-613.
282. Uno, S.; Dalton, T. P.; Derkenne, S.; Curran, C. P.; Miller, M. L.; Shertzer, H. G.; Nebert, D. W. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol., 2004, 65(5), 1225-1237.
283. -/- null mutant mice develop normally but show deficient drug metabolism. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(4), 1671-1676.
284. -/- null mutant mice. Biochem. Pharmacol., 1997, 54(10), 1127-1131.
285. +/+ mice. J. Natl. Cancer Inst., 2003, 95(16), 1227-1237.
286. Snyderwine, E. G.; Yu, M.; Schut, H. A.; Knight-Jones, L.; Kimura, S. Effect of CYP1A2 deficiency on heterocyclic amine DNA adduct levels in mice. Food Chem. Toxicol., 2002, 40(10), 1529-1533.
287. Kimura, S.; Kawabe, M.; Yu, A.; Morishima, H.; Fernandez-Salguero, P.; Hammons, G. J.; Ward, J. M.; Kadlubar, F. F.; Gonzalez, F. J. Carcinogenesis of the food mutagen PhIP in mice is independent of CYP1A2. Carcinogenesis, 2003, 24(3), 583-587.
288. Dragin, N.; Dalton, T. P.; Miller, M. L.; Shertzer, H. G.; Nebert, D. W. For dioxin-induced birth defects, mouse or human CYP1A2 in maternal liver protects whereas mouse CYP1A1 and CYP1B1 are inconsequential. J. Biol. Chem., 2006, 281(27), 18591-18600.
289. Peters, J. M.; Morishima, H.; Ward, J. M.; Coakley, C. J.; Kimura, S.; Gonzalez, F. J. Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice. Toxicol. Sci., 1999, 50(1), 82-89.
290. Buters, J. T.; Tang, B. K.; Pineau, T.; Gelboin, H. V.; Kimura, S.; Gonzalez, F. J. Role of CYP1A2 in caffeine pharmacokinetics and metabolism: studies using mice deficient in CYP1A2. Pharmacogenetics, 1996, 6(4), 291-296.
291. Matsuzaki, Y.; Nagai, D.; Ichimura, E.; Goda, R.; Tomura, A.; Doi, M.; Nishikawa, K. Metabolism and hepatic toxicity of flutamide in cytochrome P450 1A2 knockout SV129 mice. J. Gastroenterol., 2006, 41(3), 231-239.
292. Lasker, J. M.; Huang, M. T.; Conney, A. H. In vivo activation of zoxazolamine metabolism by flavone. Science, 1982, 216(4553), 1419-1421.
293. Zaher, H.; Buters, J. T.; Ward, J. M.; Bruno, M. K.; Lucas, A. M.; Stern, S. T.; Cohen, S. D.; Gonzalez, F. J. Protection against acetaminophen toxicity in CYP1A2 and CYP2E1 double-null mice. Toxicol. Appl. Pharmacol., 1998, 152(1), 193-199.
294. Smith, A. G.; Davies, R.; Dalton, T. P.; Miller, M. L.; Judah, D.; Riley, J.; Gant, T.; Nebert, D. W. Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. EHP Toxicogenomics, 2003, 111(1T), 45-51.
295. -/- triple-knockout mouse. Mol. Pharmacol., 2008, 73(6), 1844-1856.